Journal
CANCERS
Volume 12, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/cancers12102751
Keywords
endometrial cancer; small-molecule inhibitor; PI3K; AKT; mTOR; receptor tyrosine kinase; clinical trials
Categories
Funding
- Ministry of Economy and Competitiveness (MINECO) [RTC-2017-6261-1]
- European Regional Development Fund. ERDF A way to make Europe
- ESF Investing in your future by Instituto de Salud Carlos III (ISCIII) [CB16/12/00328, CB16/12/00231, PI17/02071 PI17/02155, CP19/00025]
- Grups consolidats de la Generalitat de Catalunya [2017SGR1368, 2017SGR1661]
- Asociacion Espanola Contra el Cancer (AECC) [GCTRA1804MATI]
- AGAUR-Generalitat de Catalunya
- Ministerio de Ciencia, Innovacion y Universidades, Gobierno de Espana (ES)
- Generalitat de Catalunya [SLT002/16/00315]
Ask authors/readers for more resources
Simple Summary Patients diagnosed with endometrial cancer (EC), the most common gynaecological malignancy in women worldwide, cope with a disease associated with poor prognosis and limited treatment options after first-line therapy when it reaches an advanced or metastatic stage. Lately, small-molecule inhibitors have emerged as an alternative targeted therapy, renewing hope in the fight against this disease. The aim of this review is to shed light into the current state and future prospects of small-molecule inhibitors on EC treatment by summarizing the extensive number of clinical trials that have been performed during the last years, and to provide a comprehensive up-to-date document with the most remarkable results. Despite the great effort researchers are making to improve the molecular characterization of tumours, to unravel the underlying mechanism of EC progression, and to increase the efficacy of targeted therapy, we might say that there is still a long way to pave to efficiently treat EC patients. Endometrial cancer (EC) is the sixth most common cancer in women. A continued number of low-risk EC patients at diagnosis, as well as patients diagnosed with advanced-stage disease, will experience an aggressive disease. Unfortunately, those patients will present recurrence or overt dissemination. Systemic cytotoxic chemotherapy treatment on advanced, recurrent, or metastatic EC patients has shown poor results, with median survival rates of less than one year, and median progression-free survival rates of four months. Therefore, the search for innovative and alternative drugs or the development of combinatorial therapies involving new targeted drugs and standard regimens is imperative. Over the last few decades, some small-molecule inhibitors have been introduced in the clinics for cancer treatment, but only a few have been approved by the Food and Drug Administration (FDA) for EC treatment. In the present review, we present the current state and future prospects of small-molecule inhibitors on EC treatment, both alone and in combination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available